HR 3520119th CongressIntroduced

STAND Against Emerging Opioids Act

Introduced: May 20, 2025

Healthcare

Standard Summary

Comprehensive overview in 1-2 paragraphs

This bill, introduced in the House as H.R. 3520, would add tianeptine to the federal schedule of controlled substances, specifically placing it in Schedule III of the Controlled Substances Act (CSA). The bill also extends the scheduling to include tianeptine’s analogues, salts, isomers, and salts of isomers. The scheduling would take effect 90 days after enactment. In short, the bill aims to tighten federal control over tianeptine and closely related substances, making it harder to manufacture, distribute, or possess them outside regulated channels.

Key Points

1Adds tianeptine to Schedule III of the CSA, including its analogues, salts, isomers, and salts of isomers.
2Effective date is 90 days after enactment, giving agencies time to implement the new controls.
3Short title: “Scheduling Tianeptine and Analogues Now to Defend Against Emerging Opioids Act” (STAND Against Emerging Opioids Act).
4Sponsored by Rep. Panetta (for himself and Rep. Pfluger) and referred to the House committees on Energy and Commerce and the Judiciary.
5The bill’s stated purpose is to strengthen the federal response to emerging opioid-type substances by scheduling tianeptine and related compounds.

Impact Areas

Primary group/area affected: Federal regulators and law enforcement (e.g., DEA) responsible for enforcing CSA scheduling, as well as manufacturers, distributors, and importers of tianeptine and its analogues, who would face new registration, recordkeeping, and handling requirements.Secondary group/area affected: Researchers and healthcare-related entities may need to obtain approvals or licenses to work with scheduled substances; medical or legitimate uses would be subject to CSA regulations.Additional impacts: State and local jurisdictions with existing restrictions on tianeptine may align with the federal scheduling; international trade and compliance obligations could be affected for import/export of tianeptine and related compounds. Overall, the bill would expand federal regulatory controls and penalties associated with possession, distribution, and manufacturing of tianeptine and its analogues.

Generated by gpt-5-nano on Oct 3, 2025